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2 INTRODUCTION 
 THE SPHINGOSINE-1-PHOSPHATE (S1P)  
The sphingosine-1-phosphate (S1P) is a pleiotropic and widespread bioactive molecule 
belonging to the sphingolipid family, a complex group of lipids present in all eukaryotic 
cells. Previously considered playing only structural functions, sphingolipids are now 
recognised as key regulators of a myriad of cellular mechanisms and physiological 
processes 1. Sphingolipids are amphipathic molecules, constituted by a hydrophobic 
backbone (a sphingoid long chain base), a fatty acid chain and a hydrophilic region 
(Figure1).  
 
Figure 1 The structure of sphingolipids. Examples of sphingolipids are represented. The hydrophobic 
region is constituted by a sphingoid base chain (only the sphingosine as sphingoid base chain is 
represented in the picture, in blue) which binds a fatty acid chain (in red) and an hydrophilic region (in 
green) (Modified from Futerman and Hannun, 2004) 2. 
 
The de novo pathway of sphingolipid biosynthesis, highly conserved among all the 
eukaryotes, initiates in the endoplasmic reticulum (ER) with the condensation of serine 
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and palmitoyl coenzyme A, catalysed by serine palmitoyltransferase (SPT), and leads to 
the de novo synthesis of ceramide, the hub of the sphingolipid metabolism. In 
mammalian cells, the newly produced ceramide is usually transported to the Golgi 
apparatus and the addition of different head groups, during its trafficking, converts 
ceramide into complex sphingolipids, such as the sphingomyelin (SM) and 
glucosylceramide (GluCer). Ceramide can also be produced by a stepwise degradation 
of complex sphingolipids in the lysosomes or by the activation of sphingomyelinase 
(SMase) at the plasma membrane, which metabolize SM to ceramide. The breakdown 
of ceramide by a family of ceramidases (CDases) regenerates sphingoid bases, among 
which, the sphingosine, which could be recycled in the sphingolipid pathway or 
phosphorylated to generate S1P 2,3 (Figure 2).  
S1P is produced inside the cells in different compartments by the phosphorylation of 
the sphingosine in a reaction catalysed by one of the two known isoforms of the 
sphingosine kinase (SphK1 and SphK2). The S1P levels are tightly controlled by its fast 
degradation. S1P can be dephosphorylated back to sphingosine by sphingoid base-
specific phosphatases (SPPases) SPP1 and SPP2 or by broad-specific lipid phosphatases 
known as LPPs. Alternatively, S1P can be irreversibly degraded in ethanolamine 
phosphate and hexadecenal by S1P lyase, the exit point of the sphingolipid metabolic 
pathway (Figure 2).  
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Figure 2 Sphingolipid metabolic pathway. The de novo biosynthesis (continue arrows) of sphingolipids 
and salvage (or recycling) pathway (dashed arrows) are depicted in the picture. Ceramide (Cer) 
synthetized in the ER from the condensation of Serine and Palmitoyl-CoA is transported to the Golgi 
apparatus. The transport of ceramide from the ER to the Golgi occurs either through the transfer protein 
CERT or the vescicular transport (VT). Sphingomyelin (SM) and glucosylceramide (GluCer) are synthesized 
in the latter compartment and then transported to the plasma membrane by vescicular transport. In the 
inner layer of the plasma membrane the sphingomyelinase (SMase) activated by multiple stress 
signalling metabolize the SM to Cer. SM and GluCer on plasma membrane are internalized and 
proceeding through the endosomal pathway are degraded to Cer by specific enzymes in the lysosome 
compartment. Cer is transformed by ceramidases (CDase) in sphingosine (Sph), which can be recycled to 
Cer in the ER or phosphorylated to form S1P in different cell compartments. The exit point of the 
sphingolipid metabolic pathway is the irreversible breakdown of S1P to ethanolamine phosphate and 
hexadecenal by S1P lyase.The S1P dephosphorylation by S1P phosphatases (SPPases) in ER would be 
recycled to form Cer (Petti L).  
 
Among the wide family of sphingolipids, the interest of researchers has been focused 
on S1P, since the discovery that it regulates cell growth in response to external stimuli 
4,5 and suppresses the apoptosis 6. Actually, a great corpus of studies demonstrated the 
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involvement of S1P in several physiological and pathological processes, including 
multiple sclerosis, inflammation, diabetes and cancer 7.  
The reason why S1P plays such different roles is due to its dual signalling mechanism. 
Indeed, S1P not only has different functions inside the cells as second messenger, but 
it can be transported outside the cell by different members of the ABC transporters, 
such as ABCC1 and ABCA1 8,9, and activate five specific cell surface G protein-coupled 
receptors (S1PR1-5) in autocrine or paracrine manner (the so-called ‘inside-out 
signalling’), activating different downstream signalling pathways 10 . 
 THE INTRACELLULAR S1P SIGNALLING AND THE ‘SPHINGOLIPID RHEOSTAT’   
The intracellular signalling functions of S1P have not been completely clarified yet and 
many effects previously attributed to its role as second messenger, did not completely 
excluded the involvement of the S1P receptors 1,11.  
Studies demonstrating a direct effect of S1P in the regulation of the calcium release 
from the intracellular stores, for the first time pointed out the function of S1P as a 
second messenger inside the cell 11,12. The direct interaction of S1P with intracellular 
targets has been confirmed by two interesting studies. The first one demonstrated that 
S1P is an essential co-factor for the activation of NF-kB triggered by TNFα, through the 
canonical pathway, important for inflammatory and immune processes and anti-
apoptotic responses 13. Afterwards, a recent study revealed the role of S1P in the 
nucleus. Through its binding to the histone deacetylase 1 and 2 (HDAC1-1) corepressor 
complex, S1P controls the histone acetylation and influences gene expression 14.   
S1P and ceramide are bioactive interconvertible metabolites. The sphingosine 
produced during the ceramide catabolism could be reversibly phosphorylated to form 
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S1P and in turn S1P can be dephosphorylated back to sphingosine, that can be recycled 
for ceramide biosynthesis by ceramide synthase (CerS). The concept of the 
‘sphingolipid rheostat’ was proposed after pioneering studies in vitro that 
demonstrated the involvement of S1P in the cell proliferation induction and in the 
suppression of the ceramide-induced programmed cell death 4–6,15–17. These studies 
suggested that the balance of S1P and ceramide intracellular concentration determines 
the cell fate decision between growing/surviving or dying 18,19.  However, the 
‘sphingolipid rheostat’ is not the only sphingolipid mechanism that regulates the cell 
fate. Rather, the balance between conflicting signals due to different sphingolipids, 
their localization within the cell and the activation of different enzymes and receptor 
subtypes, could influence cell behaviour (‘sphingodynamics’ model) 1. 
 THE S1P RECEPTORS (S1PRS) 
S1P is the ligand for five specific G protein-coupled receptors (GPCRs), called S1P 
receptors (S1PRs) or endothelial differentiation gene receptors (EDGRs): S1PR1/EDG1, 
S1PR2/EDG5, S1PR3/EDG3, S1PR4/EDG6 and S1PR5/EDG8 10. The S1P binds the S1PR1-
3 with high affinity (Kd=8.1nM for S1PR1, kd=27nM for S1PR2 and kd=23nM for 
S1PR3), whereas it has a lower affinity for S1PR4 and S1PR5 20. The S1PR1, S1PR2 and 
S1PR3 are ubiquitously expressed, whereas S1PR4 and S1PR5 have a narrower 
expression, respectively in the hematopoietic system and in the central nervous 
system (CNS). The S1PR1 couples exclusively with the Gi/o alpha subunit of 
heterotrimeric G proteins and activates the Ras/ERK pathway to enhance proliferation, 
the phosphatidylinositide 3-kinase (PI3K)/Akt pathway to inhibit apoptosis and the 
PI3K/Rac pathway to promote cytoskeletal rearrangement and cellular migration. The 
9 
 
S1PR2 and S1PR3 have been reported to be associated to several G proteins. Indeed, 
they couple with Gi/o and activate Ras/ERK and (PI3K)/Akt pathways. S1PR2-3 also 
couple to G12/13 enhancing the activation of Rho. These two receptors additionally 
bind Gq and activate phospholipase C (PLC). Similarly, the S1P4 and S1P5 couple with 
Gi/o and G12/13 21 (Figure 3). Since S1PRs are widespread in different cell types and 
tissues, their specific pattern of expression and their association with different G 
proteins activate several downstream pathways and determines the regulation of 
specific cellular mechanisms and physiological processes 21,22.  
 
Figure 3 The S1PR family and downstream pathways. S1P binds five G-protein coupled receptors which 
are specifically coupled to different G proteins and lead to the activation or inhibition of the indicated 
downstream signalling pathways. Abbreviations: ERK = extracellular signal-regulated kinase; PI3K = 
phosphatidylinositol 3-kinase; PLC = phospholipase C; AC = Adenylyl cyclase-cyclic AMP; JNK = Jun 
aminoterminal kinase  (Petti L). 
 
 SPHINGOSINE-1-PHOSPHATE RECEPTOR 2 (S1PR2) 
The S1PR2 is ubiquitously expressed in different cell types and tissues. Therefore, not 
surprisingly, it has been found involved in multiple physiological and pathological 
mechanisms. Although mutations of the S1PR2-like gene in zebrafish lead to evident 
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abnormalities in embryonic development, S1PR2 knock out mice are normal at birth 
and do not display any relevant anatomical defects in the development 23.  
However, important functional roles for S1PR2 have been identified in different tissues 
and organs, such as the central nervous system (CNS), the auditory and vestibular 
systems, the immune system, the liver and the kidney.  
Phenotypically, the 14% of S1PR2 deficient mice, between three and seven weeks of 
age, develop lethal spontaneous seizures associated with a higher excitability of the 
pyramidal cortical neurons 24. These seizures-prone mice displays impairment of the 
spatial working memory and increased anxiety, suggesting that S1PR2 plays an 
essential role in the development and/or maintenance of a proper neuronal 
excitability 24,25. In the central nervous system, S1PR2 is thought to be involved also in 
neurogenesis, since its inhibition enhances the migration of neural progenitor cells 
toward the brain injury area 26.  
The S1PR2 receptor is also fundamental for the auditory and vestibular systems 
functioning. S1PR2 knockout mice show deafness by one month of age associated with 
morphological abnormalities of the epithelial barrier layer and vasculature in the stria 
vascularis. These alterations are possibly due to defects in the vascular tone regulation 
of the spiral mediolar artery, which directly supplies blood to the capillaries of the stria 
vascularis 27. In line with these observations, a previous analysis of regional vascular 
function in S1PR2 knock out mice revealed an essential physiological contribution of 
S1PR2 in the maintenance of normal cardiovascular function. The deficiency of S1PR2 
resulted in a lower mesenteric and renal vascular resistance and tone and in a 
decreased responsiveness to vasoconstrictor agents 28. The first mechanism 
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hypothesized by the authors involves the vascular smooth muscle cells (VSMCs). The 
VSMCs abundantly express S1PR2 29 and have been implicated in different 
mechanisms, such as migration 30, contraction 31,32 and differentiation, through the 
regulation of the transcript expression of smooth muscle differentiating genes 33,34.  
S1P has been recently identified as the signal that promotes the activation of the 
satellite cells (SCs), skeletal and muscle stem cells, fundamental to muscle 
homeostasis, by the repression of cell cycle inhibitors via the S1PR2/STAT3-dependent 
signalling in response to injuries, thus suggesting a role for S1PR2 in the regulation of 
the muscle regeneration 35.  
Noteworthy, S1PR2 is the receptor for conjugated bile acids (CBA) in the hepatocytes. 
The CBA/S1PR2 signaling in the liver, through the activation of ERK1/2 and Akt, 
controls different hepatic metabolic pathways, such as lipid and glucose metabolism 
and the synthesis of bile acids 36.  The role of S1PR2 in the liver extends to the 
regulation of hepatocyte regeneration after injury. Indeed, the liver of S1PR2 knockout 
mice is less fibrotic and increases the hepatic regeneration after treatment with carbon 
tetrachloride 37. 
In addition, the importance of S1PR2 in the metabolism is further evidenced by its role 
in diabetes. S1PR2 pharmacological blockade and genetic deletion reduce blood levels 
of glucose, the apoptosis of pancreatic beta cells and protect against the insurgence of 
STZ-induced diabetes in mice 38.  
One of the most severe complication of the diabetes mellitus is the diabetic 
nephropathy (DN), characterized by kidney hypertrophy, glomerulus and tubular 
basement membrane thickening, and tubular interstitial fibrosis. The mesangial cells 
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proliferation and the accumulation of extracellular matrix are both hallmark of the 
disease 39. S1PR2 is upregulated in kidney of diabetic rats and in rat mesangial cells 
under high glucose conditions, increasing the expression of fibronectin through the 
activation of the MAPK pathways 40. 
The role of S1PR2 in the immune system has been reported by studies on mast cells, 
macrophages and B-cells within the germinal centre (GC). Recent studies report 
opposing results regarding the role of S1PR2 in the regulation of histamine release/ 
clearance and in anaphylaxis 41,42. A vascular gradient of S1P exists between the blood 
and interstitial fluids and a role of S1PR1 has been demonstrated in directing the 
chemotaxis of lymphocytes out of lymphoid tissues and toward S1P in blood and 
lymph 43. However, S1PR2 has been demonstrated to inhibit the macrophage 
migration in vitro and S1PR2 knock out mice displays a higher macrophage 
recruitment  in a thioglycollate (TG) peritonitis model of acute inflammation 44. Finally, 
S1PR2 plays an important role in GC B-cell positioning, since it inhibits GC B cell 
responses to follicular chemoattractants and maintains the GC homeostasis 45.  
13 
 
 
Figure 4 The S1PR2 mediates multiple physiological and pathological mechanisms. S1PR2 has different 
functions in the immune system, regulating macrophage and B-cell migration as well as the histamine 
release and clearance. S1PR2 has multiple physiological roles in the liver, where it mediates the CBA 
signalling and the cellular regeneration in response to injuries. Moreover it regulates the neuronal 
excitability and plays different functions in the biology of VSMCs. It is also involved in pathologies, such 
as the diabetes and diabetic nephropathy (Modified from Adada et al. 2013) 46. 
 
 S1P SIGNALLING IN CANCER 
Many evidences demonstrate the role of the S1P pathways in cancer. Indeed, S1P 
regulates different mechanisms involved in the tumor development and progression as 
inflammation, angiogenesis, cell growth, survival, apoptosis and migration. According 
with the ceramide-sphingosine-S1P rheostat model in mammalian cells, the relative 
amount of these three lipids determines the balance between the pro-growth and 
antigrowth signals as well as the cell fate. There are many examples showing that the 
sphingolipid rheostat is involved in cancer cell proliferation, survival, apoptosis and 
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chemoresistance 47. Most of the studies are focused on the role of the sphingosine 
kinases SphK1 and SphK2 that regulate the interconversion of sphingosine into S1P, 
driving the cell towards a survival fate 47. The first observation suggesting an oncogenic 
role of SphK1 in cancer was the transformation of NIH3T3 fibroblasts overexpressing 
SphK1 48. Despite SphK1 is not defined an oncogene, since no mutations have been 
reported in cancer yet, a wide spectrum of evidences demonstrates that cancer cells 
increase the SphK1 expression and depend on it for survival and growth (non-
oncogene addiction) 49. Nevertheless, an increased expression of the SphK1 transcript 
and protein has been detected in different human cancers, such as 
astrocytoma/glioblastoma multiforme 50,51, lymphomas 52, breast 53, lung 54 and 
gastrointestinal cancers 55–57 and it is often associated with a poor prognosis and drug 
resistance 47.  
2.5.1 S1P IN COLORECTAL CANCER 
The earliest studies dealing with the link between the sphingolipids and the colon 
carcinogenesis demonstrated a protective role of sphingomyelin (SM) against the 
development and progression of the colorectal cancer 58,59. However, the wide 
majority of the latest literature mainly focuses on the role of the S1P regulatory 
enzyme SphK1. Studies in vivo demonstrated that the deletion of SphK1 resulted in a 
decrease of the intestinal polyp size in the ApcMin/+  genetic model 56 and in lower 
incidence and multiplicity of ACF and colon cancers in the azoxymethane (AOM) 
murine model of colonic tumorigenesis 57. Moreover, Sphk1 is significantly up-
regulated in human colorectal cancer tissues and in the AOM-induced ACFs and tumors 
in the murine colon 56,57,60. The increased activity of SphK1 fuels elevated intracellular 
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S1P levels that lead to tumor development. However, it is still poor clear which of the 
S1P receptors mediates these effects. Recently, the SphK1/S1P/S1PR1 axis has come to 
light as the link between chronic inflammation and colitis-associated cancer. Indeed, 
the SphK1/S1P/S1PR1 axis has been demonstrated to regulate the production of IL-6 
and induce the persistent activation of STAT3 in epithelial cells which consequently 
leads to malignant transformation in these cells 13,61. Although these findings involve 
the S1PR1 in the inflammation-induced colorectal tumorigenesis, overall the function 
of the S1PRs and the S1P extracellular signaling in the development of colorectal 
cancer is not well investigated. 
 THE ROLE OF S1PR2 IN CANCERS 
Although S1P regulates the cell growth and apoptosis also through the activation of 
the S1P receptors, the role of the S1P/S1PRs in cancer development and progression 
appears mainly associated to cancer cell invasion and motility, lymphocyte trafficking 
and transactivation of different growth factor-activated receptors 47. Interestingly, 
some studies have pointed out the involvement of S1PR2 in the development and 
progression of different type of cancers. However, its role seems to be not univocal 
and depends on the cell-type and the tumor type and staging 46. Most of the papers 
pointed out the high-level expression of S1PR2 in cell lines derived from human and 
murine tumors compared with the other S1PRs and support an anti-tumor function of 
S1PR2 62–66. Melanoma cell lines as well as breast cancer cells have been observed to 
overexpress endogenously S1PR2 and S1PR3, whereas downregulate others S1PRs 
64,65,67. Similarly, glioma cells and human gastric cell lines revealed high levels of S1PR2 
and S1PR3 62,66. Arikawa and colleagues provided evidences that S1PR2 regulates 
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migration and invasion capabilities of melanoma cells through the regulation of Rac 
and RhoA activity 67. Moreover, in vitro studies conducted on human glioblastoma and 
gastric cell lines revealed that in these tumors S1PR2 can act as a negative regulator of 
the migration 62,63. A role of S1PR2 in the regulation of cancer cell proliferation and 
growth was first provided by studies on a human renal tumor cell line derived from a 
metastatic Wilms’ tumor (WiT49). They demonstrated that the S1P/S1PR2 pathway 
promotes the expression of the connective tissue growth factor (CTGF), 
downregulated in advanced Wilms tumors, which inhibits the proliferation of WiT49 
cell line. 68 Interestingly, in vivo studies reported that Lewis lung carcinoma and B16 
cell lines implanted in S1PR2 knockout mice grow faster and enhanced tumor 
angiogenesis and vascular maturation has been observed in these mice compared to 
the wildtype controls 69. Moreover, S1PR2 knockout mice develop lymphoma at 
advanced ages with features of a germinal center (GC) derived diffuse large B cell 
lymphoma (DLBCL) phenotype 70 and mutations affecting putative S1PR2 regulatory 
sequences have been found in > 25% of human DLBCL 71.  
In contrast, the few studies that reported a pro-cancerous role for S1PR2, attribute to 
S1PR2 a function in the modulation of tumor suppressor proteins, such as  the master 
suppressor of metastasis Brms1 46,72.  
 THE ROLE OF THE S1P/S1PRS SIGNALLING IN THE REGULATION OF THE PARACELLULAR 
PERMEABILITY 
Several in vitro and in vivo evidences demonstrated the role of the S1P/S1PRs 
signalling in the regulation of endothelial cell permeability in response to enhancing 
factors or pathological conditions 73–76. Studies using FTY720-phosphate (FTY720-P), a 
17 
 
high affinity agonist for all the S1PRs (particularly for S1PR1) except for S1PR2, 
highlighted the role of the receptor S1PR1 as a vascular permeability regulator 73,77. 
Latest studies identified also the S1PR2 and S1PR3 as key regulators of endothelial 
barrier permeability. S1PR2 has been demonstrated to enhance the vascular 
permeability of endothelial cells in vitro through the activation of its downstream 
effectors Rho, ROCK and PTEN and to mediate the pulmonary vascular permeability 
also in vivo 77. Moreover, experimental models of lung injury and endothelial 
permeability demonstrated that S1PR3 contributes to the endothelial barrier 
disruption 78. Therefore, the regulation of the endothelial permeability mediated by 
S1P depends on the balance of the signalling mediated by the S1PRs 77,79. However, 
there are few studies dealing with the role of S1P signalling on epithelial barrier 
function. Nowadays, S1P has been demonstrated to enhance the intestinal epithelial 
barrier resistance in human colorectal cancer cell line Caco-2 and in porcine- and rat-
derived intestinal epithelial cells, by reorganizing and increasing the expression of E-
cadherin and occludin 80–82. However, the involvement of the S1PRs in this mechanism 
is still unknown. 
 THE BIOLOGY OF INTESTINAL AND COLONIC EPITHELIUM 
The intestinal tract of the vertebrates is a tubal structure constituted by four tissue 
layers: the mucosa, the submucosa, the muscular layer and the serosa. The epithelium 
is the innermost constituent of the mucosal layer that lines the lumen and defines the 
interface between our internal and external environments. It is a simple cell layer, 
mainly constituted by absorptive enterocytes, columnar cells that have hydrolytic and 
absorptive functions of luminal contents, with apical microvilli that increase the 
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absorption surface 83,84. The principal functions of the small intestinal epithelium are 
the digestion and absorption of the nutrients. It is organized in crypt-villus units and it 
is constituted by four major cell type: the enterocyte, the Goblet cells, the 
enteroendocrine cells (EECs) and the Paneth cells 83. The Goblet cells produce and 
secrete mucins, peptides and proteins involved in the formation of the mucus layer, a 
highly viscous extracellular layer, that provides the first defence line against physical 
and chemical injury caused by the ingested food, microbes and microbial products  85. 
The EECs are distributed through the whole gastrointestinal tract and scattered along 
the entire crypt-villus axis and represent the 1% of the whole epithelial cell population. 
They regulate digestive enzyme secretion, metabolism, bowel motility and food intake 
acting as chemoreceptors that sense the lumen content signals and release molecules 
which enter the circulation and target epithelial cells and the nervous system 86. The 
Paneth cells are highly specialized epithelial cells present at the bottom of the crypt in 
the small intestine. They synthetize and secrete antimicrobial peptides and regulate 
the homeostatic balance between the essential colonizing microbiota and the innate 
immune protection against pathogens 87. An emerging role of the Paneth cells is to 
provide the niche signals, essential for the growth and maintenance of intestinal stem 
cells 88. The main functions of the colonic epithelium are the absorption of water and 
salts and to compact stool for the excretion. The fetal colonic epithelium is constituted 
by transitory wide and flat villi, which in humans are lost at birth. Therefore, the adult 
colonic epithelium is arranged in crypts associated with a flat luminal surface. The 
colonic epithelium is constituted by three types of epithelial cells: the enterocytes, 
alternatively called colonocytes, the enteroendocrine cells and the Goblet cells. The 
colonocytes are located at the top of the crypts and in the inter-crypt table, the surface 
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between the crypts, whereas the Goblet cells are located in the midcrypt. Although the 
colonic epithelium is lacking of Paneth cells, at the base of the crypts there are Paneth-
like cells, called deep crypt secretory cells or crypt base goblet cells, with a gene 
expression profile intermediate between goblet and Paneth cells, whose the functions 
are still unknown 84. 
 INTESTINAL STEM CELLS (ISCS) AND EPITHELIAL HOMEOSTASIS  
The intestinal and colonic epithelium is daily exposed to injuries and aggression by the 
luminal contents that induce the death of many epithelial cells. Therefore, in the adult 
epithelium a rapid and efficient mechanism of self-renewal is essential. Even if the 
debate over the real identity and position of the ISCs remains still unsolved, the 
Clevers’ group demonstrated that the self-renewal ability of the epithelium is driven by 
a small population of adult stem cells located at the bottom of the crypts, named crypt 
base columnar cells (CBCC), able to produce the whole epithelial cell lineages 89. The 
CBCCs, also called active stem cells (ASC) since they are highly proliferative, specifically 
express the leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) 
marker, the receptor for RSPO1 90. The Lgr5+ CBCC are intercalated with Paneth cells in 
the small intestine, whereas the Lgr5+ stem cells are located at the bottom of the crypt 
in the colon.  In response to an array of signals produced by the crypt niche, the CBCC 
rapidly divide to generate progenitors, better known as Transit-Amplifying (TA). TAs 
rapidly divide four to five times, start migrating upward the crypt-villus axis and 
differentiate into mitotically-inactive specialized epithelial cells that continue to 
migrate at the top of the villi (small intestine) or at the surface epithelium (colon), 
where they finally die and are extruded into the lumen 89 (Figure 5). Complete 
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epithelial turnover occurs every 3-5 days in the intestine and every 5-7-days in the 
colon. These mechanisms maintain the balance between cell production and cell death 
in the gastrointestinal epithelium.  
 
Figure 5 Epithelial self-renewal. The figure represents the self-renewal mechanisms occurring in 
intestinal (A) and colonic (B) epithelium and the differentiating hierarchy from Lgr5+ CBC into Transit-
Amplifying which while migrate upward the crypt-villus axis or at the top of the crypt, differentiated in 
enterocytes, enteroendocrine and goblet cells. Adapted from Barker et al., 2014 89. 
 
 SIGNALLING PATHWAYS INVOLVED IN THE SELF-RENEWAL OF THE INTESTINAL EPITHELIUM 
The renewal process is spatially organized and several signalling pathways are involved 
in the spatial and functional regulation of the niche compartment 83. The Wnt 
signalling was the first signalling pathway discovered to be involved in the control of 
the stem cell niche and the main regulator of the intestinal self-renewal. The members 
of the Wnt family are cysteine-rich secrete glycoproteins. Wnt proteins bind to Frizzled 
(Fz) and Lrp5/6 receptor complexes triggering the nuclear translocation of β-catenin, 
through the inhibition of the APC/Gsk-3β/Axin complex that, in absence of Wnts, 
promotes the ubiquitin-mediated degradation of β-catenin. The nuclear β-catenin 
associates with the transcription factors of the T-cell factor (TCF) family to promote the 
transcription of Wnt target genes, which regulate proliferation and differentiation 91. 
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Several studies demonstrated the role of the Wnt signalling and the downstream TCF-
4/β-catenin complex in the control of the proliferation of epithelial cells and in the 
maintenance of the epithelial stem cell compartment in the small intestine 92–94. 
Indeed, the complex TCF-4/β-catenin has been considered the ‘master switch’ that 
controls the stemness and differentiation of the intestinal epithelial cells 93.  In the last 
decade, several studies went deeper into the identification and localization of the Wnt 
family members in the murine adult intestine and colon. Nowadays, it is known that a 
subgroup among the Wnt members (Wnt3, Wnt6 and Wnt9b) and their specific 
receptors of the Frizzled (Fz-5 and Fz-7) and LRP family, are expressed by the crypt 
epithelial cells and activate the canonical pathway leading to the nuclear translocation 
of β-catenin and the activation of the TCF-4/β-catenin target genes. However, these 
studies identified other Wnt family members (Wnt-2b, Wnt4, Wnt-5a and Wnt-5b), 
expressed in the villus mesenchyme and in the mesenchyme adjacent to the surface 
epithelium in the colon, activating non-canonical signals that are thought to inhibit 
proliferation and to induce the epithelial cells differentiation 95,96. The TGF-β signalling 
is another pathway involved in the regulation of stemness/differentiation cell fate. The 
TGF-β superfamily comprises both the TGF-β family members and the bone 
morphogenetics proteins (BMPs). The BMP/TGF-β pathway is strongly activated in the 
differentiated epithelial compartment and its inhibition is essential for self-renewal of 
the ISCs 91,97,98.  
 DYSREGULATION OF THE EPITHELIAL SELF-RENEWAL MECHANISMS AND CANCER DEVELOPMENT 
As previously described, the homeostasis of the adult intestinal and colonic epithelium 
is determined by a complex interplay of mechanisms regulated by several signalling 
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pathways. Mutations that dysregulate these signalling pathways have been observed 
in both hereditary colon cancer syndromes and sporadic colorectal cancer suggesting a 
link between their role in the physiology and in the intestinal cancer development 83,93.  
The familial adenomatous polyposis (FAP) and the hereditary nonpolyposis colorectal 
cancer (HNPCC) are both autosomal-dominant cancer syndromes 83. The FAPs are 
caused by a germline mutation in the adenomatous polyposis coli (APC) gene and are 
characterized by the presence of hundreds to thousand colonic adenomas that 
develop in colorectal carcinomas (CRCs) in 100% of cases 83,99–101. These CRCs are 
characterized by chromosomal instability (CIN) and accumulating mutations in key 
oncogene and tumor suppressor genes (such as K-RAS and p53) 83,99. The APC 
mutations associated with the FAP are non-sense mutations that truncate the amino-
terminal β-catenin interacting domain of the APC protein 102. Mutations at the extreme 
5’ or 3’ of the APC locus induce attenuate forms of FAP. The HNPCCs are caused by 
germline mutations in the members of the DNA mismatch repair (MMR) complex, 
especially MLH1 and MSH2, and are characterized by microsatellite instability, since 
the cancers accumulate mutations in the microsatellite alleles. As a consequence, in 
HNPCC tumors mutations in the β-catenin gene CTNNB1, APC and TGFBR2 genes are 
usually observed 83,99.   
Inactivating mutations in APC have been observed not only in the familiar cancer 
syndromes, but also in most of the sporadic cancers 102 and, like mutations in other 
members of the Wnt pathway, they occur early during the tumor development 103,104. 
The Fearon and Volgenstein’s model of colorectal carcinogenesis, based on the 
analysis of the mutations present at different stages of the CRC development, 
proposes that key genetic alterations in oncogene and tumor suppressor genes, 
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acquired in a preferred sequence, drive epithelial cells to change their normal 
behaviour and confer characteristics advantageous to the development of sporadic 
cancers. In the adenoma-carcinoma progression, activating mutations of the Wnt 
signalling pathway are early key events and are the only ones found in the aberrant 
crypt foci (ACFs) 104,105. Mutations in RAS or B-RAF genes have been observed in 
intermediate adenomas 106, whereas genetic alterations inactivating TGFBR2 have 
been observed at later steps during CRC development and confer additional malignant 
characteristics to the adenomas. Furthermore, mutations inactivating P53 are 
coincident with the progression of colon adenomas to carcinomas 107. 
As previously described, the APC protein in complex with GSK3β and Axin binds β-
catenin, which is targeted for ubiquitination and destruction by the phosphorylating 
activity of GSK3β. The active Wnt signalling inhibits GSK3β activity and promotes the 
nuclear translocation of the β-catenin and the transcription of the Wnt target genes. 
The APC is expressed as a gradient from the bottom of the crypts, where its expression 
is nearly negative, to the luminal side in the epithelia of intestinal villi and colorectal 
crypts where it is highly expressed, opposite to the Wnt gradient 108–110. In cancer, the 
truncating mutations in APC gene or mutations in other members of the 
APC/GSK3β/Axin complex lead to the persistent activity of the Wnt signalling through 
the constitutively formation of the β-catenin/TCF-4 complex in the nucleus, which 
inhibits the differentiation and forces a progenitor-like phenotype on epithelial cells 
outside of the crypts, giving rise to aberrant crypt foci (ACFs) 93.  
The Min (multiple intestinal neoplasia) is a mutant allele of murine APC which encodes 
a non-sense mutation at the codon 850 111. The mice heterozygous for min (ApcMin ) 
develop a high number of adenomas most of all in the small intestine by 4 weeks of 
24 
 
age and have a reduced lifespan of 150 days 112. The ApcMin/+ mice are used as model of 
FAP and sporadic colorectal cancers 111. 
 THE INTESTINAL EPITHELIAL BARRIER FUNCTION AND REGULATION 
The intestinal and colonic epithelial barrier works as a defence barrier to prevent the 
passage of intraluminal microorganisms and as a filter that allows the selective 
translocation of dietary nutrients and electrolytes through transcellular or paracellular 
pathways. Indeed, the epithelial cell membranes represent the main barrier against 
hydrophilic solutes except for the presence of specific transporters that allow the 
translocation of electrolytes, sugars, aminoacids and short chain fatty acids 
(transcellular permeability). The other pathway used by the epithelium to regulate the 
translocation of solutes is the paracellular space between adjacent epithelial cells. The 
paracellular permeability is regulated by three junctional complexes localized along the 
lateral membrane of epithelial cells: the tight junctions (TJs), the adherent junctions 
(AJs) and the desmosomes 113,114. Whereas the AJs and desmosomes are thought to be 
principally involved in the mechanical linkage of epithelial cells, the main role of the TJs 
is the functional regulation of the epithelial paracellular permeability between 
adjacent cells. Indeed, the TJs are multi-protein complexes localized at the border 
between the apical and lateral membrane regions, forming a continuous belt-like ring 
around epithelial cells 115. TJs are constituted by different transmembrane proteins, 
which interact in the paracellular space with identical (homophylic interaction) or 
different (heterophylic interaction) proteins on adjacent cell membranes. The 
intracellular domains of transmembrane proteins interact with PDZ-domain-containing 
adaptor proteins (as ZO-1) that link the TJ complex to the actin cytoskeleton. The 
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proteins that constitute the TJs are occludins, claudins and junctional adhesion 
molecules (JAMs). Occludin is the first TJ protein identified 116. It is an integral 
membrane protein with two extracellular loops, a short cytoplasmic N-terminus and a 
long cytoplasmic C-terminus, which interacts with the ZO-1 protein essential to link 
occludin to the actin cytoskeleton 115. The function of the occluding is not completely 
clear yet. Indeed, although many evidences suggest a role of occludin in the TJ 
formation and in the regulation of paracellular permeability 117, these mechanisms 
seem not to depend on this protein 118. The claudins are a family of transmembrane 
proteins with four hydrophobic transmembrane domains, two extracellular loops and 
two N- and C-terminal cytoplasmic domains. The intracellular C-terminal domain binds 
the PDZ-binding domain proteins (including ZO-1, -2 and -3) which anchor claudins to 
the actin cytoskeleton. The claudins have been demonstrated to regulate the barrier 
function, however different claudins have different effects on the paracellular 
permeability 119,120.   
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3 AIMS  
Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive sphingolipid metabolite 
recognized as a critical regulator of many physiological processes including growth, 
proliferation, survival, apoptosis, migration and differentiation. The considerable 
progress made in the last twenty years in understanding cellular S1P functions has 
revealed its involvement not only in physiological, but also in pathological processes 
including cancer and inflammation. Indeed, several evidences report high tissue levels 
of S1P in many cancers influencing survival, proliferation, formation of new vascular 
vessels and metastatic dissemination 7. Intracellular S1P levels are finely regulated by 
the equilibrium between its formation and degradation. When one of these 
mechanisms, involving sphingosine kinases (SphKs) for the synthesis and S1P lyase 
(SPL) and S1P phosphatases for the degradation, is altered, the S1P is deregulated. In 
many cancers, the high levels of S1P correlated with the increased activities of SphKs 
121. On the other hand, S1P gradient plays a crucial role in lymphocyte migration and 
trafficking 122. S1P levels are normally higher in the blood and lymph than in tissues. 
Augmented S1P levels occur during inflammatory conditions, favoring the S1P-
mediated recruitment of immune cells from the blood and lymphoid organs to the 
inflamed tissues. For these aspects, enormous interest has been paid on S1P signaling 
as a new therapeutic target for cancer and immune disorders. The role of S1P in 
mediating both cancer and inflammatory processes has pointed out this signaling as 
the link between two these conditions 13,61. However, the intra- and extracellular 
mechanisms underlying this interaction are still poor clear. S1P is both an intracellular 
second messenger and the ligand of five EDG family G protein-coupled receptors 1-5 
(S1PR1-5) through which exerts most of its functions 7. Several evidences support the 
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hypothesis that, beside the alteration of SphK activity, there is also a deregulation of 
S1PR expression underlying tumorigenesis processes. Nevertheless, it is still 
controversial whether the S1PRs act as pro- or anti-tumor receptors. Among all S1P 
receptors, S1P1-3 are those ubiquitously expressed and mainly studied. Upon 
activation of a specific receptor, S1P regulates cell growth, survival, migration, 
adhesion, angiogenesis, vascular tone and permeability. Interestingly, S1PR2 seems to 
mediate opposite effects than other receptors. Indeed, whereas S1PR1 and S1PR3 
control respectively immune cell trafficking, vascular tone and formation, proliferation 
and migration, S1PR2 acts inhibiting migration and proliferation.  It is likely that the 
pro- or anti-tumor effects of the S1P/S1PRs activation depends strictly on the receptor 
involved and the tissue/cellular context 21,22. This theory could explain the 
controversial functions of a same S1PR in different tumors 123. An increasing body of 
evidence suggests that S1P signalling plays a crucial role in the intestinal 
tumorigenesis. High levels of the S1P regulatory enzyme, SphK1, were found in colon 
cancer patients. Studies in vivo demonstrated that the deletion of SphK1 resulted in a 
decrease of the intestinal polyp size in the ApcMin/+  genetic model 56 and in lower 
incidence and multiplicity of ACF and colon cancers in the azoxymethane (AOM) 
murine model of colonic tumorigenesis 57. However, the function of the S1PRs in this 
process is still unknown, as well as it is still poor clear whether the dysregulation of 
SphK1 in colon cancer activates a specific receptor. Recently, the SphK1/S1P/S1PR1 
axis has come to light as the link between chronic inflammation and colitis-associated 
cancer. Indeed, the SphK1/S1P/S1PR1 axis has been demonstrated to regulate the 
production of IL-6 and to induce the persistent activation of STAT3 in epithelial cells 
which consequently leads to malignant transformation in these cells 13,61. Although 
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these findings involve the S1PR1 in the inflammation-induced colorectal 
tumorigenesis, so far there are no evidences of S1P receptor distribution on intestinal 
epithelial cells in healthy and colon cancer tissue. Data obtained from my laboratory 
revealed an enhancement of epithelial barrier function in presence of S1P 81, 
suggesting the involvement of S1P receptors on epithelial cells. However, these effects 
were not inhibited by FTY720, a specific inhibitor with high affinity to S1PR1 and low 
affinity to S1PR3, thus excluding the role of S1PR1 in the regulation of intestinal barrier 
and pointing a potential role for other S1P receptors 81. Nevertheless, the role of S1P 
signaling and S1P receptors on intestinal epithelial cells remain to be clarified. Given 
the emerging role of S1P signaling in the intestinal carcinogenesis and the scarcity of 
knowledge on the role of S1P/S1PRs pathways in the biology and pathophysiology of 
the intestinal epithelium from which colon cancer derived, the main proposals of my 
thesis have been:  
  Aim.1 To explore the physiological functions of the S1PRs on intestinal epithelial cells 
 Task 1.1 Characterization of the S1P pathway in the intestinal epithelial cells; 
Task 1.2 Investigation of the physiological functions of the S1PRs on intestinal 
epithelial cells  
Aim.2 To explore the role of S1PR2 in intestinal tumorigenesis 
Task2.1 Analysis of S1PR2 expression in tumour biopsies from human patients 
Task2.2 Functional characterization of S1PR2 in experimental models of CRC 
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4 RESULTS 
AIM 1 TO EXPLORE THE PHYSIOLOGICAL FUNCTIONS OF THE S1PRS ON INTESTINAL EPITHELIAL CELLS  
 CHARACTERIZATION OF S1PRS IN EPITHELIAL CELLS  
4.1.1 CHARACTERIZATION OF S1PRS IN HUMAN EPITHELIAL CELLS 
In order to characterize the S1P/S1PRs pathway in the colonic epithelium, I enrolled 8 
patients which underwent colon surgery for colorectal cancer. The surgical samples 
collected from the healthy portion of the colonic tissues were processed to obtain 
mucosal biopsies and primary epithelial cells. Since the epithelial cells quickly undergo 
apoptosis when the contact between neighboring cells is lost, affecting their analysis, 
the approach I used for the isolation of primary epithelial cells was rapid and consisted 
in the collection of entire crypts from the mucosa instead of single cells, as reported in 
Figure 6A.  
Since S1PR1, S1PR2 and S1PR3 are ubiquitously expressed, whereas the expression of 
S1PR4 and S1PR5 is less widespread and mainly confined to the lymphoid and 
hematopoietic tissue and central nervous system, I focused the analysis on the first 
three receptors. I analysed the mRNA expression of S1PR1-3 by qRT-PCR both in the 
mucosa and in primary epithelial cells isolated from colonic biopsies. I observed that 
S1PR1 transcript levels were higher compared to S1PR2 and S1PR3 in the mucosa, 
whereas S1PR2 and S1PR3 mRNA were comparable to each other (Figure 6B). 
However, the analysis of the S1PR mRNA expression in primary human epithelial cells 
isolated from colonic biopsies revealed a higher level of S1PR2 compared to the S1PR1 
and S1PR3 transcripts (Figure 6B). These observations indicated an enrichment of 
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S1PR2 rather than S1PR1 and S1PR3 in the epithelial compartment. On the contrary, 
the higher expression of S1PR1 and S1PR3 in the whole mucosal tissue than in the 
epithelial cells suggested an enrichment of these receptors in non-epithelial 
compartments (Figure 6B). The immunohistochemistry analysis of mucosal S1PR2 
protein, confirmed that the receptor is highly present on epithelial cells indicating the 
epithelium as the main compartment expressing S1PR2 (Figure 6C).  
 
Figure 6 Characterization of S1PR expression in human colonic epithelial cells and mucosa. (A) Image 
of human crypts isolated from colonic biopsies. (B) S1PR1-3 mRNA expression in human epithelial cells 
(EC) (n=4) and mucosal biopsies (M) (n=4) from intestinal specimens of healthy controls by qRT-PCR. (C) 
Expression of S1PR2 (black arrows) in human colonic tissues by immunohistochemistry. Original 
magnification is 4X for the panel on the left and 20X for panels 1 and 2 on the right. 
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4.1.2 CHARACTERIZATION OF S1P RECEPTORS IN MURINE EPITHELIAL CELLS 
Since mouse experimental models have been widely used for studying biological and 
pathological processes triggered by S1P signalling, I decided to characterize the 
expression of S1PR1-3 also in the murine colonic epithelium. To this end, I isolated 
primary murine colonic epithelial cells. Then I compared the expression of the three 
receptors in the epithelium and in the whole tissue. The expression analysis of the 
transcriptional levels of S1PR1-3 confirmed that also in mouse S1PR2 was the most 
abundantly S1P receptor expressed in the epithelial cells (Figure 7A). The western blot 
analysis of S1PR1-3 proteins confirmed a greater abundance of S1PR2 in epithelial cells 
compared to the relative expression of S1PR1 and S1PR3 in the epithelial 
compartment. While the levels of S1PR1 in the epithelium appeared very low, the 
S1PR3 protein was highly present, but its relative expression was lower than S1PR2 
(Figure 7B-C). To better localize the S1PR2 expression in the mucosa, I performed an 
immunohistochemistry staining on colon sections. Interestingly, the staining showed a 
marked positivity for S1PR2 in the plasmatic membrane and cytoplasm of the epithelial 
cells localized at the top of the crypts (Figure 7D). The absence of commercially 
available antibodies for the detection of S1PR1 and S1PR3 by immunohistochemistry, 
impeded the localization in the mucosa of these receptors. However, altogether these 
data demonstrated that the S1P/S1PR axis is present on intestinal epithelial cells and 
that, among the three major S1P receptors, S1PR2 is the most abundant in the healthy 
epithelium. 
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Figure 7 Characterization of S1PR expression in the murine colonic tissues. (A) S1PR mRNA expression 
in murine epithelial cells (n=6) and colon (n=4) of wild type mice. (B) Densitometric analysis of S1PR 
protein expression in colonic epithelial cells and colon relative to β-Actin by Western blot. (C) 
Representative image of the Western blot. (D) Expression of S1PR2 in normal murine colonic tissue by 
Immunohistochemistry. Original magnification is 10X for the panel on the left and 20X for panel 1 on the 
right.  
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 ANALYSIS OF THE PHYSIOLOGICAL FUNCTIONS OF THE S1PRS ON INTESTINAL EPITHELIAL CELLS 
4.2.1 ANALYSIS OF THE ROLE OF S1PR2 IN COLONIC EPITHELIAL PERMEABILITY 
Given the abundant constitutive expression and unknown functions of S1PR2 in 
intestinal epithelial cells, I decided to focus my studies on its role in the epithelium. 
Intestinal epithelial cells constitute a physical barrier against bacterial and dietary 
antigens and regulate the passive movement of solutes through spaces between 
adjacent epithelial cells (paracellular permeability). It was shown that the activation of 
S1PR2 on endothelial cells caused a disruption of endothelial adherens junctions and 
increased paracellular permeability 77. I hypothesized therefore that S1PR2 could also 
be involved in the regulation of the epithelial barrier permeability. To assess this 
hypothesis, I took advantage of total knockout mice for S1PR2 (s1pr2-/-) and I 
determined the colonic permeability in vivo on naïve S1PR2 knock out mice and wild 
type littermates (s1pr2+/+) by the Evans Blue assay. This method is based on the in vivo 
perfusion of the colon with the Evans Blue dye, which physiologically does not 
translocate through the epithelial barrier. In presence of mucosal damage which leads 
to alteration of epithelial barrier function, the Evans Blue dye penetrates through the 
mucosa and the amount of the dye translocated into the intestinal wall correlates with 
the grade of barrier dysfunction. The Evans Blue assay performed on healthy s1pr2-/- 
and s1pr2+/+ mice did not reveal any macroscopic difference in colonic permeability 
(Figure 8A). The intestinal barrier function depends on the expression and distribution 
of an apical junctional complex, which is composed of both tight and subjacent 
adherens junctions. Therefore, to confirm that the loss of S1PR2 does not affect the 
intestinal barrier permeability, I analysed the mRNA expression of genes coding for 
three members of TJs proteins involved in the regulation of the epithelial barrier 
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permeability, i.e. occludin (ocln), claudin-2 (cldn-2) and Zonula occludens-1 (tjp-1), in 
colonic epithelial cells isolated from s1pr2-/- and s1pr2+/+ mice. The analysis of tjp-1, 
claudin 2 and occludin transcripts in the epithelial cells did not reveal any significant 
difference between the two groups indicating that the complete deletion of S1PR2 
does not affect the normal intestinal barrier function (Figure 8B). The intestinal barrier 
is constituted by heterogeneous cells including differentiated epithelial cells known as 
goblet cells that participate in the regulation of intestinal epithelial barrier by the 
production of mucins. In order to explore the role of S1PR2 in secreted barrier 
function, I analysed the distribution of mucins in naive wildtype and S1PR2 knock out 
mice performing a combined Alcian blue-PAS staining, which allows to differentiate 
neutral and acidic mucins. As reported in Figure 8C, no differences were observed in 
the distribution of the different mucins in the colon of wild type and S1PR2 knockout 
mice, indicating that S1PR2 in intestinal epithelium does participate in epithelial 
barrier regulation.  
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Figure 8 Analysis of the colonic epithelial barrier permeability in naïve s1pr2-/- mice. (A) Quantification 
of the basal colonic permeability in s1pr2-/- (n=3) and s1pr2+/+ (n=3) mice by the Evans blue assay. (B) 
qRT-PCR analysis of the TJs mRNA basal expression in colonic epithelial cells isolated from s1pr2-/- (n=5) 
and s1pr2+/+ (n=3) mice. (C) Representative image of the mucin distribution in s1pr2-/- and s1pr2+/+ by 
Alcian blue-PAS staining. 
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I further investigated whether the loss of S1PR2 would accelerate the dysregulation of 
the epithelial barrier permeability occurring under acute inflammation. To this 
purpose, I assessed the permeation of the Evans Blue dye in s1pr2-/- and s1pr2+/+ 
littermates after DSS-induced colitis. The status of the disease was assessed daily 
monitoring body weight loss, bleeding and faecal consistency. After 10 days of 3% DSS 
administration mice displayed a strong colitis with a compromised epithelial barrier 
function. I did not observe any difference neither in clinical parameters associated with 
the colitis (Body weight, DAI, colon length) between s1pr2-/- and s1pr2+/+ mice, nor in 
the inflammation score (Rachmilewitz score) (Figure 9A), thus indicating no differences 
in colitis susceptibility between two groups. Moreover, the analysis of the Evans Blue 
dye permeation did not reveal any significant difference between the two groups 
further supporting the conclusion that the S1PR2 does not regulate the intestinal 
epithelial barrier permeability (Figure 9B).  
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Figure 9 Analysis of the colonic permeability in s1pr2-/- mice with DSS-induced acute colitis. (A) Clinical 
parameters associated with acute colitis (percentage of body weight, disease activity index and colon 
length) and colonic inflammation score (Rachmilewitz score) in s1pr2-/- (n=9) and s1pr2+/+ (n=5) mice 10 
days after acute colitis induction with 3% DSS provided ad libitum. (B) Colonic epithelial permeability by 
Evans blue assay in s1pr2-/- (n=3) and s1pr2+/+ (n=3) mice 10 days after acute colitis induction. 
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4.2.2 S1PR2 DEFICIENCY INCREASES THE PROLIFERATION OF COLONIC EPITHELIAL CELLS IN VIVO 
Since several studies reported that S1PR2 controls the proliferation in different cell 
types, such as murine embryonic fibroblasts and rat hepatocytes in vitro 124,125, I 
analysed whether S1PR2 could regulate the proliferation also of intestinal epithelial 
cells. To this end, I evaluated intestinal epithelial cell proliferation in vivo in s1pr2-/- 
mice. The colonic tissues of untreated 8 weeks old female s1pr2-/- and s1pr2+/+ mice 
have been collected and formalin-fixed two hours after the intraperitoneally injection 
of the BrdU (5mg/kg). The BrdU has been detected by immunohistochemistry and the 
analysis of the proliferation has been performed by counting the average number of 
BrdU positive cells per 20 crypts in three different areas. Since the presence of regional 
differences in the proliferation rate between different colonic regions has been 
reported 126–128, we analysed separately proximal, middle and distal colon. Although 
the analysis of the whole colon did not show any difference between s1pr2-/- and 
s1pr2+/+ mice, a significant higher proliferation was observed in middle colonic 
epithelial cells of the s1pr2-/- mice compared with s1pr2+/+ mice (p=0.034) (Figure 10A-
B).  
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Figure 10 Analysis of the epithelial proliferation in vivo in s1pr2-/- mice. (A) Representative image of the 
BrdU positive cells in the epithelium of the medial colon of s1pr2-/- and s1pr2+/+  mice. (B) Analysis of the 
BrdU incorporation in the proximal, medial, and distal colonic/rectal epithelium of s1pr2-/- (n=3) and 
s1pr2+/+ (n=3) mice.  
40 
 
4.2.3 IN VITRO INHIBITION OF S1PR2 INDUCES EPITHELIAL CELL PROLIFERATION  
Due to the well-known difficulty of propagating long-term primary intestinal epithelial 
cell cultures, to further investigate the role of the S1PR2 in epithelial cell proliferation 
in vitro, I used the Caco-2 cell line derived by human epithelial colorectal 
adenocarcinoma. Before assessing the proliferation, I analysed the expression of S1PRs 
in Caco-2 cell line by RT-PCR, which confirmed the exclusive expression of S1PR2 using 
primary colonic fibroblasts as positive control for the S1PR expression (Figure 11A). 
Thus, I cultured Caco-2 cells in presence of different concentrations of the specific 
S1PR2 inhibitor (JTE013) and/or its ligand S1P and I evaluated cell proliferation after 24 
hours by the BrdU incorporation assay. We observed that the treatment with JTE013 in 
a range of 0.4-0.08 μM significantly increased the normal proliferative activity of 
epithelial cell after 24 hours (Figure 11B). The choice of the range of the inhibitor 
concentrations was based on the pharmacological characteristics of the inhibitor (IC50 
value=0.017 μM). Although I did not observe changes in the BrdU incorporation, when 
Caco-2 cells were stimulated with different concentrations of the S1P (10-7M-10-5M) 
alone, the treatment with the highest concentration of ligand (10-5M) reversed the 
JTE013-induced increase of the proliferation to basal conditions (Figure 11C). Overall in 
vitro and in vivo results demonstrated that the inhibition of the S1PR2 activity 
increases colonic epithelial cell proliferation and suggested that the S1P/S1PR2 axis is 
responsible for keeping under control the proliferation in colonic epithelial cells. 
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Figure 11 The S1PR2 inhibition increases the proliferation of Caco-2 epithelial cells in vitro. (A)  Analysis 
of S1PR mRNA expression in Caco-2 cells by qRT-PCR. (B) Brdu incorporation assay in Caco-2 cells after 
24-hour treatment with different concentrations of the S1PR2 selective antagonist JTE013 (0.016µM-
2µM) and (C) with different concentration of S1P (10-7M-10-5M) in presence or absence of JTE013 0.4 µM. 
EGF=epithelial growth factor; Mmc = mitomycin C. Significance versus the vehicle is represented by * 
(p=0.015 for the JTE013 0.4 µM and p=0.023 for JTE013 0.4 µM + S1P10-7M treatments). Significance 
versus JTE013 0.4 µM + S1P10-5M treatment is represented by # (p=0.007 for JTE013 0.4 µM and p=0.009 
for JTE013 0.4 µM + S1P10-7M treatments). 
 
 
AIM 2 TO EXPLORE THE ROLE OF S1P RECEPTOR 2 IN INTESTINAL TUMORIGENESIS 
Considering that, on the one hand the deregulated cell proliferation is a key event that 
propels the tumour cell expansion and on the other hand the evidences of S1PR2 
involvement in the development and progression of different type of cancers 62–64,68,70, 
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I aimed at studying whether S1PR2 might play a role in the development and 
progression of the colorectal cancer. 
 ANALYSIS OF S1PR2 EXPRESSION IN TUMOUR BIOPSIES FROM HUMAN PATIENTS 
To address this hypothesis, I firstly characterized the expression of S1PR2 in human 
colon cancer (CRC) samples. For this purpose, I analyzed adenomas and 
adenocarcinomas samples collected from patients with CRC from the Humanitas 
biobank. To explore the role of S1PR2 in the different stages starting from very early 
stages, we selected T1N0M0 and T2N0M0 adenocarcinomas (based on the 
Tumor/Node/Metastasis (TNM) classification for colon cancer), whose extension is 
restricted to mucosa, submucosa and muscolaris propria (T1 and T2) and did not 
spread nor in lymph nodes (N0), nor in distant organs (M0). Additionally, in order to 
exclude any interference due to the chemotherapy, I included only specimen from 
patients without any treatments. As healthy controls, I analyzed colonic biopsies 
collected from areas surgically resected 10 cm distant from the tumor and therefore 
not affected by the tumor itself. The S1PR2 expression was analyzed by western blot 
on protein lysates. As shown in figure 12, the relative expression of S1PR2 protein was 
significantly lower in both adenocarcinomas T1N0M0 and T2N0M0 compared to 
normal colonic mucosa (p=0.02 and p=0.04 respectively). The same trend was also 
observed analyzing the protein lysates extracted from adenomas. 
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Figure 12 S1PR2 protein expression in human CRC biopsies and healthy colonic tissues. 
Characterization of S1PR2 protein expression in human adenomas (n=4), adenocarcinomas T1 (n=4), 
adenocarcinomas T2 (n=7) and healthy colonic mucosa (n=8) from colonic specimens of patients with 
CRC by western blot. (A) Representative image of S1PR2 protein expression in four sample of healthy 
colonic mucosa and five samples of adenocarcinomas. In (B) the quantification of the relative S1PR2 
expression by densitometric analysis and normalization on the β-actin expression.  
 
 THE FUNCTIONAL ROLE OF S1PR2 IN EXPERIMENTAL MODELS OF CRC 
In order to gain insight into the potential role of S1PR2 in the intestinal tumorigenesis, 
I took advantage of S1PR2 knockout mice. Indeed, I assessed the development of 
tumors in s1pr2-/- compared to wild type mice employing a model of inflammatory-
driven colorectal cancer. Tumorigenesis was induced by a single intraperitoneal 
injection of the carcinogen Azoxymethane (AOM) (10 mg/kg) followed by four cycle of 
four days DSS (2.5% ad libitum) spaced out by ten days of water. Body weight, faecal 
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bleeding and consistency were monitored at least twice a week during the experiment. 
At the day of the sacrifice, the tumours were analysed firstly by colon endoscopy and 
then the colon was collected for the histological evaluation of the inflammatory score 
and the number of dysplasia of each type. I did not observe any significant difference 
neither in the clinical parameters, such as body weight loss, disease activity index (DAI) 
and colon length, nor in the inflammation score between s1pr2-/-and s1pr2+/+ mice 
(Figure 13), thus confirming previously shown data observed in acute induced colitis 
and demonstrating that the loss of S1PR2 does not worsen intestinal inflammation.  
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Figure 13 Clinical parameters and inflammation score in s1pr2-/- and s1pr2+/+ mice with inflammation-driven CRC. (A-
B) Clinical parameters analysed in s1pr2-/- (n=5) and s1pr2+/+ (n=6) mice: percentage of the body weight, DAI and colon 
length at the day of the sacrifice. (C) Total score of the colonic inflammation by histological analysis (Rachmilewitz 
score). 
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However, the endoscopic analysis of the colorectal region revealed a significant higher 
count of polyps in s1pr2-/- compared to wildtype mice (p=0.027) (Figure 14A). This 
result was further confirmed by the histological analysis. Indeed, a higher number of 
colonic adenomas characterized by a high grade of dysplasia (HGA) (p=0.024) (Figure 
14B right panel) and larger carcinomas (p=0.0006) (Figure 14B left panel) were found 
in s1pr2-/- mice compared to s1pr2+/+ mice. Overall these results suggested that S1PR2 
exerts an anti-tumor function and that the increased susceptibility to develop 
colorectal cancer observed in S1PR2 knockout mice was not correlated to the grade of 
inflammatory response.  
 
Figure 14 S1pr2-/- mice develop a higher number of dysplasia in AOM/DSS-induced CRC model. (A) 
Representative images of colorectal endoscopies and endoscopic analysis of the tumor number in s1pr2-/- 
(n=5) and s1pr2+/+ (n=6) mice. (B) Blinded histological analysis of number and grade of the tumors in 
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s1pr2-/- (n=5) and s1pr2+/+ (n=6) mice. The graphs represent the number of colonic tumor per mouse and 
the size of the carcinomas. 
 
To further confirm these results, I explored the role of S1PR2 in a genetic model of 
colorectal cancer, Apcmin mice, which reproduce the spontaneous and inherited 
mutations occurring early in the colorectal cancer development in human. To this 
purpose, I crossed s1pr2-/- mice with Apcmin/+ mice and I analysed the number of high 
and low-grade adenomas (HGA and LGA) and carcinomas (K) in Apcmin/+ and 
s1pr2+/+/Apcmin/+ littermates. Colon and small intestine were collected from 21-week-
old s1pr2-/-, when the polyps are established and a single-blinded histological analysis 
was performed. In accordance with this model, only three out of five s1pr2+/+/Apcmin/+ 
mice showed one or two colonic polyps, whereas all mice developed high number of 
polyps in the small intestine. By contrast, all s1pr2-/-/Apcmin/+ mice developed colonic 
lesions and the number of polyps per mouse in the s1pr2-/-/Apcmin/+ group was 
significantly higher (2.750 ± 0.9574 average) compared to the s1pr2+/+/Apcmin/+ mice 
(0.8000 ± 0.8367 average) (Figure 15A). Interestingly, the analysis about the number of 
polyps per mouse at different grade of dysplasia showed that s1pr2+/+/Apcmin/+ 
developed few colonic LGAs (0,4000 ± 0,8944 average), HGAs (0,4000 ± 0,5477 
average) and K (0,2000 ± 0,4472 average), whereas s1pr2-/-/Apcmin/+ mice did not show 
any colonic LGAs, few HGAs (0,2500 ± 0,5000 average) and a higher number of 
carcinomas (2,500 ± 1,291 average) (Figure 15B). By analysis of the tumor size, no 
difference between colonic HGAs in s1pr2-/-/Apcmin/+ mice compared to the Apcmin/+ has 
emerged, whereas the colonic carcinomas of s1pr2-/-/Apcmin/+ mice were larger (0.4600 
± 0.1578 cm) than the only one carcinoma observed in Apcmin/+ (0.3 cm) (Figure 15C).  
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Figure 15 Characterization of colonic tumors in s1pr2-/-/Apcmin/+ and s1pr2+/+/Apcmin/+ mice. A 
representative image of colonic tissue of 21-week-old S1PR2-/-/Apcmin/+ and S1PR2+/+/Apcmin/+ mice (HE 
staining) (A left panel). (A right panel, B and C) The graphs represented the histological analysis of 
number, grade and size of the tumors in colonic tissues of 21-week-old s1pr2-/-/Apcmin/+ (n=4) and 
s1pr2+/+/Apcmin/+ (n=5) mice.  
 
In contrast, no significant difference was observed in the number and size of small 
intestinal polyps between s1pr2-/-/Apcmin/+ and s1pr2+/+/Apcmin/+ mice (Figure 16A-B).  
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Figure 16 Analysis of polyps in the small intestine of s1pr2-/-/Apcmin/+ and s1pr2+/+/Apcmin/+ mice. The 
graphs represent the hystological analysis of tumor number per mouse (A) and size (B) in the small 
intestine of 21 week-old s1pr2-/-/Apcmin/+ (n=4) and s1pr2+/+/Apcmin/+ (n=5) mice. 
 
Overall these data demonstrated that s1pr2-/-/Apcmin/+ mice are more susceptible to 
develop colonic tumors, corroborating the crucial anti-tumorigenic role of S1PR2 in the 
intestinal tumor development.  
Furthermore, in line with human results, the analysis of S1PR2 in different stage of 
tumors showed a strong decrease of its expression not only in early-stage 
adenocarcinomas (Figure 17B), but also in low grade adenomas compared to normal 
epithelium (Figure 17A). These observations raised further the suspect that S1PR2 
down-regulation could be an early event during cancer development. 
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Figure 17 Expression of S1PR2 in murine colonic adenomas and carcinomas. (A) Representative image 
of S1PR2 expression in LGA (dashed lines) within colonic tissues of 21 week-old Apc min/+ performed by 
immunohistochemistry. (B) Representative images of S1PR2 expression in early-stage adenocarcinomas 
(dashed lines) within colonic tissues of 21 week-old Apc min/+ mice (left panel) and wild type mice under 
AOM/DSS treatment (right panel). The asterisks highlight the adjacent areas of normal epithelium.  
 
 
 POTENTIAL MECHANISMS OF S1PR2-MEDIATED COLORECTAL CANCER DEVELOPMENT 
Role of the S1PR2 in the intestinal renewal and epithelial differentiation in organoids 
The epithelial surface is continually renewed by intestinal epithelial stem cells (IESCs) 
that reside at the crypt base. However, the exact mechanisms that regulate IESC 
proliferation, differentiation and functional potential are not completely known. Since 
the pharmacological inhibition of S1PR2 increases the proliferation of epithelial cells in 
vitro and the expression of S1PR2 was mainly observed in the differentiated epithelial 
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cells characterized by a low proliferative rate in the upper region of the crypts in the 
colon and at the top of the crypts and in the villi in the small intestine (Figure 7D-18A), 
I hypothesized that S1PR2 could act as a master regulator for intestinal epithelial 
differentiation. To verify this hypothesis, I isolated small intestinal crypts from normal 
C57BL6/N mice and put them in culture in order to obtain organoids. Organoid display 
many important functions of the normal intestinal epithelium. They originate from the 
proliferation and differentiation of Lgr5+ intestinal stem cells located inside of the 
crypts. Initially IESCs form villus-like cystic structures, then proliferate resulting in 
outward buds containing also intestinal differentiated cells. The final structure 
characterized by multiple branches and the localization of the different cell type within 
the mini-gut epithelium, reflect the villus-crypt axis and the cellular localization in vivo. 
The organoids obtained from s1pr2+/+ mice were untreated or treated thirty minutes 
per day with JTE013 at different concentrations (10 µM, 1 µM and 0,01 µM) for three 
consecutive days, starting from six hours after the plating of the crypts within 
Matrigel®. After 48 hours, the crypts treated with the higher concentration of the 
S1PR2 inhibitor formed fewer branched enteroids that were maintained until the 
complete mini-gut formation (Figure 18B). On the contrary both lower concentrations 
of JTE013 did not show any difference in the morphology of the organoids compared 
to the untreated ones (data not shown). These data demonstrate that the inhibition of 
S1PR2 during the organoid development blocks the complete formation of the 
branches. The round morphology of organoids raises the possibility that the inhibition 
of S1PR2 could prevent the epithelial differentiation. To gain insight into this 
hypothesis, I extracted the mRNA from organoids at day 7 of development after three 
treatment with 10 µM, 1 µM and 0,01 µM of JTE013 and I assessed the expression of 
52 
 
stem cell and differentiation markers for different lineages. I evaluated the levels of 
the stemness markers Olfactomedin-4 (Olfm4) and Leucine-rich repeat-containing G-
protein coupled receptor 5 (Lgr5). Olfm4 is highly expressed in the murine intestinal 
crypt base columnar cells (CBC) and it has been recently emerged as a highly specific 
marker for stem cells 129. The Lgr5 gene encodes for a G-protein coupled receptor for 
R-spondins, a family of Wnt pathway agonists and it is a component of the Wnt 
receptor complex. Lgr5 gene is exclusively expressed by cycling columnar cells at the 
crypt base and Lgr5+ cells generate all epithelial lineages within the intestinal 
epithelium 90, suggesting Lgr5 being a stem cell marker. Additionally, I evaluated the 
expression of the intestinal differentiation markers Lysozyme (Lyz) encoding for the 
secretory product of Paneth cell; Mucin 2 (Muc2), the glycoprotein secreted 
specifically by Goblet cells and Chromogranin A (ChrA), a soluble protein produced by 
enteroendocrine cells. Interestingly, the analysis showed a strong significant increased 
expression of both Olfm4 and Lgr5 stemness markers under S1PR2 inhibition at the 
highest concentration, whereas no difference in the expression of differentiation 
markers was observed between organoids treated with both high and low 
concentrations of JTE013 or vehicle (Figure 18C). These results suggested that the 
inhibition of S1PR2 altered the crypt-villus differentiation axis inducing an increase of 
the relative expression of the stemness markers, thus maintaining the organoids in an 
undifferentiated status. 
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Figure 18 The in vitro inhibition of S1PR2 increases the expression of the epithelial stem cell markers. 
(A) Immunohistochemistry for S1PR2 in the small intestine of C57BL6 mice. (B) Organoid development at 
the day 1, 2 and 3 and 7 treated with 10 μM JTE013. (C) Gene expression analysis of stemness and 
differentiation epithelial markers at the day 7 of the organoid development in controls and upon 
treatment with different concentration of JTE013, by qRT-PCR.   
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5 DISCUSSION 
Sphingosine-1-phosphate (S1P) is a ubiquitous lipid-derived metabolite whose 
synthesis and degradation is finely regulated by sphingosine kinases (SphKs), S1P lyase 
(SPL) and/or S1P phosphatases. Its widespread physiological roles are well known and 
studied, covering cell growth, proliferation, survival, apoptosis, migration and 
differentiation. S1P can act as an intracellular second messenger or by binding to a 
family of five G protein-coupled receptors, namely sphingosine 1 phosphate receptors 
(S1PR1-5). Interestingly, S1PR1, S1PR2 and S1PR3 are widely expressed throughout all 
the tissues, whereas the S1PR4 and S1PR5 expression is restricted to the 
lymphoid/hematopoietic tissue and the central nervous system, respectively 10. 
Although S1P signaling has been extensively studied in the intestine, most at 
pathological conditions, interestingly only one study reported the expression of S1PRs 
in the intestinal epithelial cells, showing only the presence of S1PR1 and the absence 
of S1PR3 in the rat small intestinal epithelial cell line 80. The present research study 
covered the gap in the characterization of S1PR1-3 on human and/or murine colonic 
epithelium. The analysis on the epithelium partition, finely derived from the isolation 
of the human intestinal crypts from healthy subjects, revealed that among the S1PRs, 
the S1PR2 was the most abundant. Similarly, the S1PR2 was highly expressed in 
respect to the other receptors on wild type murine colon-derived epithelial cells, both 
at the transcript and protein levels and its localization at the colonic epithelium is also 
confirmed by immunohistochemistry. On the contrary, S1PR1 and S1PR3 were mainly 
localized in other non-epithelial compartments, since they showed a low expression on 
epithelial cells and a very high expression in the whole mucosal or colonic tissues. 
Based on these findings, I focused my studies on the role of S1PR2 in the colonic 
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epithelium. The gut mucosa is a highly dynamic system characterized by the interplay 
between enterocyte, tight junction and mucin proteins covering the surface of 
intestinal epithelium. This organization functionally works as a defence barrier and is 
fundamental for the intestine physiology. The knowledge of this fine balance, managed 
by the epithelium compartment, is not fully depicted to date. Few studies have 
focused on the role of the S1P signalling on the intestinal epithelial cell integrity, 
reporting the S1P function in controlling epithelial barrier permeability in murine 
intestinal and human colonic Caco-2 epithelial cell lines in vitro 80,81. However, there 
are no evidences of which sphingosine receptor is responsible of S1P-mediated effects. 
My data showed that the epithelial permeability of the colon of S1pr2-deficient mice 
did not display any dysregulation compared to wild type mice in physiological 
conditions. In fact, the gene expression of the tight junction claudin-2, occludin and tjp-
1 in the epithelial cells, were not significantly different in absence of S1PR2. Finally, the 
characterization of the mucin pattern did not show any significant difference between 
the wild type versus S1PR2 knockout mice. These data have been also confirmed in in 
vivo model of acute inflammation. In fact, the loss of S1PR2 does not significantly 
increase the epithelial barrier permeability in inflamed gut. These results suggest that 
S1PR2 is not involved in the S1P signalling-dependent regulation of the epithelial 
barrier.  
The intestinal and colonic epithelium is daily exposed to injuries and aggression by the 
luminal contents that induce the death of many epithelial cells. Therefore, in the adult 
epithelium, a rapid and efficient mechanism of self-renewal is essential. The highly 
proliferative ability of the intestinal epithelium is driven by a small population of cells 
located at the bottom of the crypts 90. Several studies reported that the S1P signalling 
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controls cell growth 4 and only few papers showed the anti-proliferative role of the 
S1PR2 in different cell lines 37,125. To date, the role of S1PR2 in the proliferative 
capability of the intestinal epithelium cells is still unknown. In line with my data on the 
epithelium, I found a higher expression of s1pr2 in immortalized human Caco-2 cell line 
in comparison to s1pr1 and s1pr3 and, accordingly with the literature data 37,125, the 
pharmacological inhibition of S1PR2 increased the proliferation rate of the Caco-2 cell 
line. These data have been also confirmed in in vivo studies in which the BrdU 
incorporation assay showed an increased proliferation of epithelial cells in the medial 
colon of S1PR2 knockout mice compared to the wild type. Interestingly, the BrdU 
positive epithelial cells were located at the crypt bottom where the epithelial stem 
cells as well as the transit-amplifying (TA) cells are usually localized 130,131. It has been 
well accepted that stem cells are responsible of the proliferative activity of the crypts 
and that these two pathways (proliferation and differentiation) are intimately coupled 
in the intestinal epithelial cells, with the β-catenin/TCF-4 complex regulating both 
these processes. Indeed, this complex has been identified as the master switch 
between proliferating progenitors and differentiated epithelial cells both in healthy 
and malignant intestinal stem cells 93. Importantly, I found that S1PR2 was mostly 
localized at the upper region of both colon and intestinal crypts as well as in the villi, 
whereas no expression was detected on the stem cell and TA compartment at the base 
of the crypts. This observation sustains the hypothesis that the receptor has a role 
during the differentiation of the epithelial cells. The role of S1PR2 in the intestinal 
epithelium differentiation has been strengthen by using the three-dimensional mini-
gut culture system that is a powerful tool to investigate the regenerative properties of 
intestinal stem cells 91,132. The pharmacological inhibition of S1PR2, during the early 
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phases of the organoid development blocked the complete formation of the organoid 
branches and kept them in a round shape, most probably associated with an 
undifferentiated phenotype 133. The higher expression of the two stem cell gene 
markers Lgr5 and Olfm4 in the organoids treated with the S1PR2 inhibitor confirmed, 
at the gene level, the undifferentiated phenotype observed. This remark points out a 
novel role for S1PR2 in promoting differentiation of the intestinal epithelial cells as 
well as promotes this receptor as a master player in the maintenance of the crypt-
villus differentiation axis. This results are also proved by the literature data proposing 
the involvement of S1PR2 in the differentiation of smooth muscle cells 33 and in the 
regulation of the skeletal muscle regeneration 35. 
The primary driving forces behind the proliferation and/or differentiation of epithelial 
cells in the intestinal crypts is the Wnt/β-catenin/TCF-4 signalling. Indeed, this pathway 
has been identified as the master switch between proliferating progenitors and 
differentiated epithelial cells, both in healthy and malignant intestinal stem cells. In 
fact, the epithelial cells carrying mutations that aberrantly activate the Wnt pathway 
become unresponsive to physiological signals of differentiation and keep to behave as 
progenitor stem cells developing thus tumor lesions in surface epithelium 93. Several 
studies have revealed the involvement of S1PR2 in the development and progression 
of different type of cancers. However, its role is not univocal and it depends on the 
tissue, on the tumour kind and on its staging. Most of the in vitro and in vivo studies 
investigated the high-level expression of S1PR2 in cell lines derived from human and 
murine tumours compared with the other S1PRs and supported the anti-tumour 
function of the S1PR2 62,64–67. The relevance of the S1P pathway in the development of 
the CRC has emerged in the last years as mediated by the activation of the S1PR1 
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134,135. However, the overall function of the S1PRs in the development of colorectal 
cancer, in particular of the S1PR2, is not completely understood. In line with our 
previous data on epithelial cells, we found a higher expression of s1pr2 compared to 
s1pr1 and s1pr3 transcripts (found to being very low or undetectable) in seven human 
cancer cell lines derived from colorectal adenocarcinomas and carcinomas (data not 
shown). These observations advise that S1PR2 is ubiquitously expressed in malignant 
cells and suggest a role for this receptor in the regulation of the malignant cell 
properties. A key role of the S1PR2 in the development of colorectal cancer has been 
confirmed by the analysis of the AOM/DSS-induced tumor development in S1PR2-null 
mice, which display a higher number of high grade adenomas and larger carcinomas 
compared with wild type mice, whereas no difference in the clinical parameters of 
inflammation has been observed between S1PR2 knockout and wild type mice. These 
observations indicate that the loss of S1PR2 leads to an increased onset and a faster 
progression of colorectal cancers independently of inflammatory conditions. The 
analysis of tumors in the Apcmin/+ genetic model of intestinal and colon cancer further 
confirmed this hypothesis. Indeed, a higher incidence and size of tumors in the colon 
of s1pr2-/-/Apcmin/+ mice compared to s1pr2+/+/Apcmin/+ controls was also observed. A 
strong decrease of the S1PR2 expression was observed in adenomas and early staged 
human carcinomas and also in the murine adenomatous polyps and adenocarcinomas 
of both AOM/DSS and genetic models, suggesting that S1PR2 down-regulation is an 
early event required for the development of colorectal cancers. Overall these data 
displayed for the first time a protective role of the S1PR2 during colon carcinogenesis. 
In the context of the tumorigenic model, which associates the tumorigenesis with the 
maintenance of a stem phenotype, I propose that the S1PR2 may contrast the 
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tumorigenesis by promoting differentiation and anti-proliferative pathways and 
blocking malignant transformation of epithelial cells (Figure 19). 
 
Figure 19 Model of the role of S1PR2 in the colonic tumorigenesis. Epithelial stem and progenitor cells 
highly proliferating at the half bottom of the crypts accumulate nuclear β-catenin and express β-
catenin/TCF target genes. When they reach the midcrypt the β-catenin/TCF activity is downregulated, 
the cell cycle is blocked and the cells started to differentiate. Moreover, when mutations that aberrantly 
activate the Wnt pathway occur, epithelial cells become independent from the physiological signals 
which control the β-catenin/TCF-4 complex and continue to behave as crypt progenitor cells in the 
surface epithelium. On the contrary S1PR2 is not expressed by cells at the bottom of the crypts, whereas 
it is present in the cells at the top of the crypt near the lumen. Since in tumors the expression of S1PR2 is 
down-regulated, we hypothesize that S1PR2 by blocking the proliferation and inducing the 
differentiation pathways, may contrast the malignant transformation of the epithelial cells (Adapted 
from van de wetering, 2002 93).      
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6 MATERIALS AND METHODS 
 HUMAN TISSUE COLLECTION 
I enrolled in the study 16 patients underwent colon surgery for colorectal cancer and 
after having informed the patients about the goals of my study, I obtained a written 
consensus. Healthy colonic specimens have been obtained from these patients. The 
colonic tissues have been processed to obtain mucosal biopsies and isolate epithelial 
cells. Moreover, I obtained from Humanitas biobank 15 human biopsies of adenomas 
(n=4) and adenocarcinomas (n=11). Among the adenocarcinoma samples I selected 
tumors classified as T1N0M0 (n=4) and T2N0M0 (n=7), on the bases of the 
Tumor/Node/Metastasis (TNM) classification for colon cancer. Both biopsies and 
epithelial cells have been frozen in dry ice and homogenized for the mRNA and protein 
extractions. Human studies were approved by the ethics committee of the Istituto 
Clinico Humanitas (Rozzano, Italy). 
 MICE AND ANIMAL MODELS 
Mice were housed in pathogen-free conditions. The S1pr2-/- mice were kindly provided 
by Dr Richard L. Proia (NIH, Bethesda, MD) 136 and heterozygous mice were bred to 
generate S1pr2-/- and S1pr2+/+ littermates. Apcmin/+ were purchased from the Jackson 
Laboratory. S1pr2-/- and Apcmin/+ mice were crossbred to obtain S1pr2-/-/Apcmin/+ and 
S1pr2+/+/Apcmin/+ littermates. The genotypes were determined by PCR analysis of 
genomic DNA extracted from tail biopsies. The primer sequences used for the 
genotyping of the S1pr2 mice are: 5’- GCA GTG ACA AAA GCT GCC GAA TGC TG-3’, 5’- 
AGA TGG TGA CCA CGC AGA GCA CGT AG -3’ and 5’- TGA CCG CTT CTT CGT GCT TTA 
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CGG TAT -3’ 136. The primer sequences used for the Apcmin/+ mice genotyping are 5’- 
GCC ATC CCT TCA CGT TAG -3’, 5’- TTC CAC TTT GGC ATA AGG C -3’ and 5’- GTG CAA 
TCC ATC TTG TTC AAT -3’. The acute colitis mouse model was induced in 8-12-week-old 
female S1pr2-/- and S1pr2+/+ littermates by administration of 3% DSS in drinking water 
ad libitum for ten days. The body weight, stool consistency and faecal bleeding were 
daily monitored and scored as previously described. The disease activity index (DAI) 
has been evaluated according to the criteria proposed by Cooper et al 137 as the mean 
of the body weight loss (0=none, 1=1-5%, 2=5-10%, 3=10-15%, 4=>15%), stool 
consistency (0=normal, 2=loose, 4=diarrhea) and faecal bleeding scores (0=none, 
2=occult bleeding, 4=bleeding). At day 10 the Evans blue dye permeation assay has 
been performed in treated mice or the mice have been immediately sacrificed and the 
colon collected, fixed overnight in 4% formalin, processed and paraffin embedded. The 
inflammation-driven colon carcinogenesis model was induced by a single 
intraperitoneal injection with the Azoxymethane (AOM), 10mg per kg body weight, 
followed by four cycles of DSS 2.5% in drinking water ad libitum for four days spaced 
out by ten days. The body weight of the mice, the faecal bleeding and consistency 
were monitored at least twice a week and the DAI evaluated as previously described. 
The tumor development has been monitored by endoscopy after the last DSS cycle and 
the colon has been collected and fixed in 4%. The 21-week-old S1pr2-/-/Apcmin/+ and 
S1pr2+/+/Apcmin/+ littermates have been sacrificed and the colon and intestine collected 
and fixed in 4% formalin. The fixed colon and intestine have been processed, paraffin 
embedded, sectioned in 2μm slides and stained with hematoxilin (Dako) and eosin 
(Diapath) for the single-blinded histological evaluation of the inflammation 
(Rachmilewitz score) and tumor count, or immunostained. All the procedures involving 
62 
 
mice were carried out with the approval from the ethics committees of the Istituto 
Clinico Humanitas, conformed to institutional guidelines in agreement with national 
and international law. 
 EVANS BLUE DYE PERMEATION ASSAY 
The mice have been anesthetized with Ketamin and Xilazine. The abdominal quadrant 
of peritoneum has been opened in correspondence of the caecum, which together 
with the proximal region of the colon was completely exposed. A tiny cut in the 
proximal region of the colon nearby the caecum has been performed and a catheter 
has been inserted into the lumen and secured with suture. The anus has been exposed 
and another catheter has been fixed into the anal lumen with suture. The Evans blue 
solution 0.1% has been perfused into the colonic lumen flowing through the two 
catheters 1ml/min for five minutes and then washed to remove the excess of Evans 
blue dye. The mice have been sacrificed and the colon has been collected and let dry 
overnight. The overnight incubation of the colon with Dimethyl-formamide allow the 
dissolution of the Evans blue dye into the solution. The amount of the Evans blue into 
the solution has been quantified as the spectrophotometric optical density (OD) at 620 
nm wavelength and the colon permeability evaluated as the ratio between optical 
density and the weight of the colon (Figure 20). 
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Figure 20 The Evans Blue dye permeation assay. 
(Adapted fom Vetrano S) 
 
 
 ISOLATION OF HUMAN INTESTINAL EPITHELIAL CELLS 
The colonic tissues obtained by surgical resection of the colon have been washed with 
PBS without calcium and magnesium to remove the superficial mucus. The mucosal 
layer has been isolated from the whole tissue, cut into 1cm pieces and washed in 2mM 
DTT for 15 minutes to remove the residual mucus. The mucosa was then cut into 
smaller pieces and incubated in 1Mm EDTA for 30 minutes, to chelate the calcium 
essential for the epithelial junctions. Then the crypts have been collected by vortexing 
the tissue and pelleted. 
 ISOLATION OF MURINE COLONIC EPITHELIAL CELLS 
The protocol I used for the isolation of the murine colonic epithelium for mRNA and 
protein extraction has been proposed by Nik and Carlsson 138. The colon extracted 
from the abdominal cavity has been washed flushing the lumen with ice-cold PBS 
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without calcium and magnesium. The entire colon has been inverted by inserting a thin 
crochet hook into the lumen, securing the rod end with suture and pulling the rod back 
(Figure 21A). Then, one end has been closed with suture and the other has been fitted 
to the tip of an Eppendorf Combitip plus and secured by suture. The tissue has been 
incubated in ice-cold BD Cell Recovery Solution (BD Biosciences) 20 minutes on ice, 
inflating with the Combitip plunger every 5 minutes (Figure 21B). Following the 
incubation, the colon has been rinsed by dipping it in cold PBS and the detached 
epithelium has been gently recovered with a cell scraper (Figure 21C). The recovered 
tissue has been centrifuged and the pellet immediately frozen in dry ice. 
 
Figure 21 Isolation of murine colonic epithelial cells. (A) A thin crochet hook has been inserted into the 
lumen, secured with suture and then pulled back to invert the colon. (B) One end has been closed with 
suture and the other end has been fitted to the tip of an Eppendorf Combitip plus. The tissue has been 
incubated in ice-cold BD Cell Recovery Solution and inflated with the Combitip plunger every 5 minutes. 
(C) Removal of the epithelial sheet after  incubation (Modified by Nik and Carlsson, 2013) 139.  
 ISOLATION OF MURINE INTESTINAL EPITHELIAL CELLS FOR ENTEROID CULTURE 
For the isolation of intestinal crypts, I adapted the protocol provided by Mahe in the 
Current Protocols in Mouse Biology journal 140. I extracted the intestine from the 
abdominal cavity and washed the lumen with ice-cold PBS to remove all the faeces. 
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The intestine has been opened lengthwise, cut into 2 cm pieces and washed in ice-cold 
PBS. The tissue has been further cut in smaller pieces and incubated in PBS 2mM EDTA 
for 30 minutes. Then the crypts have been collected by shaking the tissue and filtering 
the solution through a 70-µm filter to remove the villus fraction. The crypts isolated 
have been counted and plated within the Matrigel®. The crypts have been cultured in 
complete DMEM/F12 medium (B27 supplement, N2 supplement, PenStrep, hepes, 
Glutamine, 500 ng/ml R-spondin1 (Peprotec), 100 µg/ml Noggin (Peprotec) and 50 
ng/ml murine EGF (Peprotec)) and the budding enterospheres completely developed 
after 7 days. 
 WESTERN BLOT ANALYSIS 
The tissue biopsies were mechanically homogenized in the Lysis Buffer (TrisHCl ph7.4 
50mM, EDTA ph8 1mM, NaCl 150mM, 1% Triton, 0.5% Sodium Deoxycholate, 0.1% 
Sodium dodecyl sulfate) by a short 25-30Hz shaking with a bead in 2-ml tubes, through 
the bead mill Tissue Lyzer II (Quiagen) and kept on ice for 30 minutes. The murine 
epithelial cells have been homogenized by disrupting mechanically the pellet by a 18G-
needle syringe in the Lysis Buffer. Samples were centrifuged at 12000 g for 20 minutes 
at 4°C and the protein concentration of the supernatants were evaluated with the DC 
protein assay kit (Biorad). The protein content from each sample were separated on 
10% polyacrylamide gel and transferred to a nitrocellulose membranes (Biorad) on 
nitrocellulose membranes. The nonspecific binding sites were blocked with 5% milk for 
one hour. The membranes were incubated with the primary and horseradish 
peroxidase (HRP)-conjugated secondary antibodies. The immunoreactivity was 
detected by an enhanced chemiluminescence reaction (ECL) and developed by the 
66 
 
ChemiDoc Imaging System. Primary antibodies used for western blot were anti 
mouse/human rabbit S1P1 (1:200; LSBio LS-C137385), anti-mouse/human S1PR2 rabbit 
(1:200; Acris AP01198PU-N), anti mouse/human rabbit S1P3 (1:1000; LS-C138479), and 
anti-actin C-11 (1:1000 Santa Cruz sc-1615). Secondary antibodies used were anti 
rabbit HRP and anti goat HRP. The expression is represented as the densiometric 
analysis of protein relative to the actin.  
 RNA EXTRACTION, INVERSE TRANSCRIPTION AND QUANTITATIVE REAL TIME POLYMERASE CHAIN 
REACTION (QRT-PCR) 
Total RNA has been extracted from human and murine epithelial cells using the 
RNeasy® Lipid Tissue kit (Quiagen) according to the manufacturer’s protocol. The 
homogenization step with stainless steel beads (5 mm mean diameter) has been 
performed to properly disrupt the pellet. The mRNA has been retrotranscribed in cDNA 
by using the High Capacity cDNA Reverse Transcription Kits (Applied Biosystem) and 
quantitative real-time PCR has been performed using the Fast SYBR® Green Master Mix 
(Applied Biosystems) and detected with 7900HT Sequence Detection System (Applied 
Biosystems). The primer sequences used are reported in the Table 1. The GAPDH gene 
has been used as housekeeping. The relative mRNA expression has been evaluated as 
2-ΔCt.  
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Table 1 
 
 IMMUNOISTOCHEMISTRY  
The colonic and intestinal paraffin embedded tissue slides have been deparaffinized 
and any antigen retrieval procedure has been performed. The inhibition of the 
endogenous peroxidase has been performed with hydrogen peroxide 3% and the 
Rodent Block M (Biocare Medical RBM961) has been used for blocking the endogenous 
mouse IgG and non-specific background. The primary antibody used for the S1PR2 
staining was the anti-mouse/human rabbit S1PR2 antibody (1:200 Acris AP01198PU-
N). For the primary antibody detection, the MACH 1 Universal HRP-Polymer (Biocare 
Medical) and the Betazoid DAB Chromogen Kit (Biocare Medical) have been used. The 
combination of the alcian blue and the PAS techniques has been used to distinguishing 
neutral and acid mucins. The Alcian/PAS staining has been performed on colonic 
tissues fixed in formalin 4% according to the protocol. After deparaffinization the 
sections are stained with the standard Alcian Blue (pH 2.5) and the Periodic Acid 1%. 
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 STATISTICAL ANALYSIS 
The Prism (GraphPad) software was used for statistical analysis. Data were analysed 
with a two-tailed unpaired Student’s t-test and the p-value was considered significant 
when smaller than 0.05.   
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7 FUTURE PERSPECTIVES 
There are a several issues we plan to address to strengthen our findings. Some of them 
are already on the way to be solved and others have been planned for the next future.  
Overall these concerns regard: 
1. demonstrating the hypothesis that the S1PR2 protein appear to be expressed in 
differentiated epithelial cells whereas it is absent in the region of the crypt where 
usually are located stem and progenitor cells. Indeed, taking advantage of the Lgr5-
EGFP-IRES-creERT2 mice, expressing GFP in Lgr5 (a well-known marker of 
stemness) positive stem cells, I would like to confirm preliminary data which 
showed a differential expression of the S1PR2 between stem cells and 
differentiated epithelium (data not shown). 
2. Identifying the S1PR2 downstream pathways and genes involved in the protection 
of the tumor development especially by the investigation on the role of the S1PR2 
in the modulation of Wnt/β-catenin gene target.  
3. Analysing whether S1P and/or other sphingolipids are involved in the S1PR2 
functions in tumour development. 
4. Characterizing the expression of S1PR2 in different stage of human tumours. 
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8 CONCLUSION REMARKS 
 
My thesis has brought to light several novelties on the knowledge of S1P signalling and 
in particular on S1PR2 in intestinal epithelium.  In detail: 
1. S1PR2 is the most abundant S1P receptor being expressed in the colonic epithelium.  
2. S1PR2 is not involved in the mechanism controlling intestinal barrier function; 
3. S1PR2 is a crucial player in the proliferation of the colonic epithelial cells and its 
absence dramatically promotes an increase of the colon tumour onset 
4. S1PR2 may have a prominent role into the differentiation of intestinal stem cells 
acting as a new regulator of epithelial differentiation.  
Although further studies are necessary, my results shed light not only on the molecular 
mechanisms underlying intestinal tumorigenesis, but also point to S1PR2 as a new potential 
target for the treatment of colon cancer.   
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